𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase II Study of Doxorubicin and Bevacizumab for Patients With Metastatic Soft-Tissue Sarcomas

✍ Scribed by D'Adamo, D. R.


Book ID
125502540
Publisher
American Society of Clinical Oncology
Year
2005
Tongue
English
Weight
365 KB
Volume
23
Category
Article
ISSN
0732-183X

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


Randomized comparison of doxorubicin and
✍ Ernest C. Borden; David A. Amato; John H. Edmonson; Paul S. Ritch; Masanori Shir πŸ“‚ Article πŸ“… 1990 πŸ› John Wiley and Sons 🌐 English βš– 589 KB

Two treatment regimens for metastatic soft-tissue sarcomas were compared in a randomized trial in the cooperative group setting. Histopathologic diagnosis was affirmed by pathology reference panel review in 72% of the 347 patients. In 21% of patients, the reference panel affirmed the diagnosis of so

A phase II study of ifosfamide/mesna wit
✍ Brian M. J. Cantwell; James Carmichael; Sarah Ghani; Adrian L. Harris πŸ“‚ Article πŸ“… 1988 πŸ› Springer 🌐 English βš– 418 KB

In a phase II study, 16 adult patients with locally advanced or metastatic soft tissue sarcomas were treated with i.v. infusions of ifosfamide/mesna 5 g/m2 plus i.v. doxorubicin 40 mg/m2. Courses were given every 3 weeks up to a maximum of six courses in responding patients. Six patients (37.5%) had

A phase II trial of temozolomide in pati
✍ Susan M. Talbot; Mary Louise Keohan; Mary Hesdorffer; Russell Orrico; Emilia Bag πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 69 KB πŸ‘ 3 views

## Abstract ## BACKGROUND The objective of this study was to assess the efficacy and toxicity of the imidazotetrazine derivative temozolomide for patients with unresectable or metastatic soft tissue sarcoma. ## METHODS Twenty‐five of 26 patients were eligible and assessable for toxicity and resp